fda deadline semaglutide Warns on Certain Forms of Compounded FDA crackdown on off-brand Ozempic

This trend was not apparent in the placebo group (Supplementary Figure S2)

Setiawan 2017)

Hims, as the company is often referred to, has become one of the most prominent public faces of compounded semaglutide, offering it in more than 30 states and spending nearly $145 million in a single quarter on marketing its drugs, which include injections with the same active ingredient as Ozempic and Wegovy alongside other weight loss offerings that have attracted tens of thousands of customers

Public attitudes toward GLP-1 weight loss remain divided Weight loss medications such as GLP-1RAs have improved obesity treatment, with drugs like semaglutide and tirzepatide helping many individuals lose significant weight